A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity by Martin-Killias, P et al.
 Published OnlineFirst November 12, 2010.Clin Cancer Res 
  
Patricia Martin-Killias, Nikolas Stefan, Sacha Rothschild, et al. 
  
ActivityDesigned Ankyrin Repeat Protein has Potent Anti-tumor 
A Novel Fusion Toxin Derived from an EpCAM-specific
  
Updated version
  
 10.1158/1078-0432.CCR-10-1303doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://clincancerres.aacrjournals.org/content/suppl/2011/01/03/1078-0432.CCR-10-1303.DC1.html
Access the most recent supplemental material at:
  
Manuscript
Author
edited. 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been
  
  
  
  
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
.permissions@aacr.orgDepartment at
To request permission to re-use all or part of this article, contact the AACR Publications
Research. 
on March 14, 2014. © 2010 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 12, 2010; DOI: 10.1158/1078-0432.CCR-10-1303 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.  
Copyright © 2010  American Association for Cancer Research 
 
 
A Novel Fusion Toxin Derived from an EpCAM-specific Designed 
Ankyrin Repeat Protein has Potent Anti-tumor Activity 
 
 
Patricia Martin Killias 1, Nikolas Stefan 1, Sacha Rothschild 2, 3, Andreas Plückthun*1 
and Uwe Zangemeister-Wittke *1, 4 
 
 
 
 
1 Department of Biochemistry, University of Zürich, Winterthurerstrasse 190, 8057 
Zürich, Switzerland 
2 Department of Clinical Research, University of Bern, Murtenstrasse 35, 3010 Bern, 
Switzerland 
3 Department of Medical Oncology, University Hospital Bern, Freiburgstrasse 10, 
3010 Bern, Switzerland 
4 Institute of Pharmacology, University of Bern, Friedbühlstrasse 49, 3010 Bern, 
Switzerland 
 
* Corresponding authors: AP, Email: plueckthun@bioc.uzh.ch, Tel: +41-44-635 5570, 
FAX +41-44-635 5712, and UZW Email: uwe.zangemeister@pki.unibe.ch,  
Tel: +41-31-632 3290, FAX: +41-31-632 4992 
 
 
Running title: Tumor targeting with a DARPin-toxin fusion protein 
Key words: Cancer therapy, Designed Ankyrin Repeat Proteins, EpCAM, fusion 
toxin, tumor targeting 
Grant support: Swiss National Science Foundation for UZW and AP (310030-
119859), Krebsliga of the Kanton Zürich for UZW and AP. 
 
 Published OnlineFirst on November 12, 2010 as 10.1158/1078-0432.CCR-10-1303
Research. 
on March 14, 2014. © 2010 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 12, 2010; DOI: 10.1158/1078-0432.CCR-10-1303 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.  
Copyright © 2010  American Association for Cancer Research 
 
 
Translational Relevance 
 
Antibodies or antibody fragments are widely used as targeting moiety for the delivery 
of cytotoxic drugs to tumors. However, many of these constructs have limitations due 
to their poor expression and aggregation tendency. To overcome these limitations, 
we used for the first time Designed Ankyrin Repeat Proteins (DARPins) as non-IgG 
scaffolds with favorable biophysical properties and much higher expression yield in 
E. coli and systematically tested their potential for tumor-targeted delivery of a highly 
potent biotoxin in preclinical studies. The fusion toxin Ec4-ETA" recognizing the 
carcinoma-associated antigen EpCAM was potently cytotoxic against carcinoma cell 
lines of various histotypes in vitro. In athymic mice targeting of human carcinoma 
xenografts with Ec4-ETA" resulted in a strong anti-tumor response including 
complete regressions. This demonstrates that DARPins are well suited for tumor 
targeting and that the fusion toxin Ec4-ETA" holds promise for clinical development. 
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Abstract 
 
Purpose: Designed Ankyrin Repeat Proteins (DARPins) hold great promise as a new 
class of binding molecules to overcome the limitations of antibodies for biomedical 
applications. Here, we assessed the potential of an EpCAM-specific DARPin (Ec4) 
for tumor targeting as a fusion toxin with Pseudomonas exotoxin A. 
Experimental design: DARPin Ec4 was genetically fused to a truncated form of 
exotoxin A (ETA") and expressed in E. coli. The cytotoxicity of Ec4-ETA" was 
measured against tumor cell lines of various histotypes in vitro. Tumor localization 
and anti-tumor activity were determined in mice bearing two different EpCAM-positive 
tumor xenografts.  
Results: Ec4-ETA" expressed very well in soluble form in the cytoplasm of E. coli and 
yielded up to 40 mg after purification per liter culture. The protein was monomeric 
and the disulfides of ETA" formed spontaneously. Ec4-ETA" bound to EpCAM with 
low nanomolar affinity, similar to free Ec4. Furthermore, it was highly cytotoxic 
against various EpCAM-positive tumor cell lines in vitro with IC50 values less than 
0.005 pM. This effect was competed by free Ec4, but not by unspecific DARPins. 
Upon systemic administration in athymic mice, Ec4-ETA" efficiently localized to 
EpCAM-positive tumors to achieve maximum accumulation 48-72 h after injection, 
whereas an irrelevant control fusion toxin did not accumulate. Tumor targeting with 
Ec4-ETA" resulted in a strong anti-tumor response including complete regressions in 
some animals. 
Conclusions: Our data demonstrate for the first time the potential of DARPins for the 
generation of protein therapeutics for tumor targeting, and that Ec4-ETA" deserves 
attention for clinical development. 
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Introduction 
 
The concept of tumor-targeted therapy is based on the use of conjugates 
consisting of ligands binding to tumor-associated antigens or growth factor receptors 
which deliver cytotoxic agents selectively to tumors, while sparing normal tissues 
from destruction (1). These agents include radioisotopes, small organic compounds, 
antisense oligonucleotides and protein toxins. All of them exert different modes of 
action, compared to standard chemotherapy, and thus might be particularly useful to 
combat drug-resistant cancer. Nonetheless, it remains to be shown in every single 
case whether a tumor-specific localization actually occurs and what profile of anti-
tumor action compared to side effects is seen. 
Immunotoxins are a class of conjugates in which antibodies or antibody 
fragments are chemically linked to protein toxins, whereas in the more advanced 
constructs targeting ligand and toxin are genetically fused (2,3). The most popular 
toxins used for this purpose are diphtheria toxin and Pseudomonas aeruginosa 
exotoxin A (ETA) (4), which both act by irreversibly inhibiting protein synthesis in 
cells. In ETA-based fusion toxins a truncated variant lacking the cell binding domain 
and carrying a C-terminal KDEL peptide (denoted here ETA") is commonly used (5). 
Currently, several of these fusion toxins are in clinical trials for the treatment of 
lymphomas, leukemias (6,7), mesothelioma and cancers of the ovary, pancreas and 
bladder (8,9). 
On solid tumors, well investigated targets for antibody-based therapies are 
members of the epidermal growth factor receptor family, such as EGFR itself and 
ErbB2, and certain tumor-associated carbohydrates (2,10). The epithelial cell 
adhesion molecule (EpCAM) has also emerged as a promising structure for targeted 
therapy of solid tumors. One reason is that its efficient internalization promotes 
access of surface bound effector molecules to intracellular targets (11-14). EpCAM is 
a homophilic cell adhesion molecule of 39 to 42 kDa, consisting of an extracellular 
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domain with an epidermal growth factor-like and a human thyroglobulin-like domain, 
and a short cytoplasmic domain. Its processing by regulated intramembrane 
proteolysis releases a cytoplasmic tail which activates the wnt signaling pathway and 
induces transcription of c-myc and cyclins (15,16). How this mechanism contributes 
to tumor progression in vivo is unclear. EpCAM is expressed at low levels on 
basolateral cell surfaces of some normal epithelia (17). On the other hand, high 
levels of homogenously distributed EpCAM are detectable on cells of epithelial 
tumors (15,18), and its overexpression represents an independent prognostic marker 
for reduced survival in patients with breast and ovarian cancer (19,20). Recently, 
EpCAM was also identified as a marker of cancer-initiating cells in colon (21), breast 
(22), pancreatic (23) and hepatocellular carcinomas (24) providing the opportunity to 
target stem-like cells, which usually respond poorly to standard therapy. The 
favorable properties of EpCAM for cancer therapy are currently exploited in phase II 
clinical trials with a scFv-ETA" immunotoxin (9,11-13) which we developed 
previously. 
The tumor-targeting moiety for the delivery of cytotoxic agents including 
protein toxins is usually derived from antibodies or antibody fragments, which, 
however, have practical limitations due to their poor expression yield and aggregation 
tendencies, at least for some constructs (25,26). Since for fusion toxins no other 
feature of the antibody than antigen binding is required, a solution might come from 
the use of alternative non-IgG binding scaffolds as targeting moieties (27). These can 
be engineered for improved specificity, affinity, and stability to increase the 
production yield. One such protein class are Designed Ankyrin Repeat Proteins 
(DARPins) (28,29). The ankyrin repeat motif consists of 33 amino acids forming a 
loop, a β-turn and two antiparallel α-helices connected by a tight turn. Their high 
stability and favorable biophysical properties provide proteins which tolerate 
engineering procedures usually not applicable to antibodies. Moreover, they contain 
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no cysteine which can instead be introduced for site-specific modifications. Thus, 
DARPins fulfill the requirement of almost ideal candidates for many biomedical 
applications including tumor targeting. Using combinatorial libraries of DARPins 
along with selection by ribosome and phage display, we recently generated several 
binders specific for EpCAM1, and demonstrated their potential for efficient delivery of 
therapeutic siRNA into tumor cells (14). 
Here we describe for the first time the use of a high-affinity DARPin (Ec4) 
specific for EpCAM to generate a fusion toxin with ETA". Ec4-ETA" expressed very 
well in E. coli, was easily purified to high yields, and proved to be specifically 
cytotoxic against various EpCAM-positive tumor cell types in vitro. In vivo, 
fluorescence imaging and therapy studies in athymic mice demonstrated its ability to 
efficiently localize to subcutaneously growing tumors upon intravenous 
administration, and induce strong anti-tumor effects including complete regressions. 
 
                                                 
1 Patricia Martin Killias, Nikolas Stefan, Sascha Wyss-Stoeckle, Annemarie Honegger, Uwe 
Zangemeister-Wittke and Andreas Plückthun. “DARPins recognizing the tumor-associated antigen 
EpCAM selected by phage and ribosome display”. In preparation. 
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Material and Methods 
 
Tumor cells 
The squamous cell carcinoma cell line of the tongue CAL27 and the colorectal 
carcinoma cell line HT29 were obtained from DSMZ (Deutsche Sammlung von 
Mikroorganismen and Zellkulturen, Braunschweig, Germany). The breast carcinoma 
cell line MCF7 and the non-Hodgkin's lymphoma cell line RL were obtained from 
ATCC (American Type Culture Collection). The small cell lung carcinoma cell line 
SW2 was maintained in our laboratory. All cells were cultured in Dulbecco's modified 
medium (DMEM) (Sigma, Buchs, Switzerland), supplemented with 10% fetal calf 
serum (Amimed, Bioconcept, Allschwil, Switzerland), 100 units/ml of penicillin and 
100 µg/ml of streptomycin (Sigma). Cells were incubated at 37°C in a humidified 
atmosphere containing 5% CO2. All cells were tested negative for mycoplasma using 
MycoAlert (Lonza, Basel, Switzerland). 
 
Construction, expression and purification of DARPin-ETA" fusion toxins 
The EpCAM-specific high-affinity DARPin Ec4 was selected from a DARPin library as 
described1, the control DARPins off7 (targeting the maltose binding protein) and 
E3_5 (an unselected member of the N3C library) have been described elsewhere 
(29,30). The sequences encoding the DARPins were inserted via BamHI and HindIII 
upstream into an expression vector derived from pQE30, containing a 12 amino acid 
linker (GSG4)2 and the 40 kDa truncated form of ETA252-608KDEL (ETA") which was 
cloned as described (11,31). ETA comprises residues Glu252-Pro608 (numbering of 
the mature protein), fused to a C-terminal his tag followed by KDEL (denoted ETA252-
608KDEL or ETA"). 
 For purification and detection the construct in addition contains an MRGS-
His6 tag at the N terminus. The DARPin-ETA" fusion proteins were expressed in 
soluble form in the E. coli strain BL21(DE3) (Stratagene, La Jolla, USA). Cultures 
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were harvested 4 h after induction with 1 mM IPTG. For purification the bacteria were 
resuspended in TBS400 (50 mM Tris, 400 mM NaCl, pH 7.4 at 4°C) with 20 mM 
imidazole and lysed with a TS 1.1 kW cell disruptor (Constant Systems Ltd., 
Northants, United Kingdom). Upon centrifugation (48000 g, 30 min at 4°C) and 
filtration (pore size 0.22 µm), the fusion toxins present in the clear supernatant were 
purified by immobilized metal ion affinity chromatography (IMAC) using Ni-NTA 
superflow (Qiagen, Hilden, Germany). 
 
Endotoxin removal 
For in vivo application, the DARPin-ETA" fusion toxins were further purified to 
eliminate endotoxin. To this end, an additional washing step with 150 column 
volumes phosphate buffered saline (PBS) containing 20 mM imidazole and 0.1% 
Triton-X-114 was performed during Ni-NTA purification, followed by size exclusion 
chromatography using a Superdex 200 10/300 GL column (GE Healthcare, Zürich, 
Switzerland). Monomeric fractions were further depleted of residual endotoxin by 
passage over an EndoTrap Red column (Hyglos, Regensburg, Germany), and the 
final endotoxin content was determined using a Limulus amebocyte lysate (LAL) 
endochrome kit (Charles River, Sulzfeld, Germany). 
 
Measurement of EpCAM-binding affinity 
Surface plasmon resonance 
The EpCAM-binding affinities of Ec4 and Ec4-ETA” were measured by surface 
plasmon resonance using a ProteOn XPR36 (Bio-Rad Laboratories, Hercules, USA) 
instrument. For ProteOn measurements one ligand channel of a Neutravidin (NLC) 
Sensor Chip was coated with 500 resonance units (RU) of the extracellular domain of 
EpCAM (residues 1 to 242 of the mature protein) biotinylated using a C-terminal 
AviTag. Kinetic data were obtained by parallel injection of different concentrations of 
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Ec4 or Ec4-ETA" ranging from 0.32 to 31.6 nM at a buffer flow of 60 µl/min in PBS 
pH 7.4 containing 3 mM EDTA and 0.005% Tween-20. Data evaluation was 
performed using the ProteOn Manager software (Bio-Rad).  
 
Flow cytometry.  
The binding affinity of Ec4 to EpCAM expressed on cells was measured by flow 
cytometry, and the equilibrium dissociation constant KD was determined as the ratio 
of dissociation rate over association rate. MCF-7 cells were pre-incubated for 30 min 
at 37°C in PBS supplemented with 1% bovine serum albumin (Sigma) and 0.2% 
sodium azide (Fluka, Buchs, Switzerland) to inhibit internalization. For dissociation 
experiments, 3 x 105 cells were saturated for 1 h at 4°C with 100 nM Ec4 labeled with 
Alexa Fluor 488 C5 maleimide (Molecular Probes, Invitrogen, Basel, Switzerland) via 
a C-terminal cysteine (Ec4cA488). Cells were centrifuged and resuspended in 1 µM 
Ec4 to prevent rebinding. The mean fluorescence intensities (MFIs) were recorded at 
different time points ranging from 0 to 4 h. For association experiments, 3 x 105 cells 
were incubated with 2.5, 7.5 or 22.5 nM Ec4cA488 and measured at time points 
ranging from 1 to 60 min without prior washing. To correct for the small amount of 
non-specific binding, probably cause by Alexa Fluor 488, the association of a non-
binding DARPin labeled with Alexa Fluor 488 was measured and subtracted. Data 
evaluation was performed with Prism (Graphpad). 
 
Disulfide assays 
The formation of the two disulfide bonds in Ec4-ETA" after purification of protein 
expressed in the cytoplasm was quantified according to (32). Briefly, 1.25 nmol of 
fusion protein was treated with 4,4′-dithiodipyridine (4-DPS) in the presence of 8 M 
urea and compared to an equally treated sample reduced with sodium borohydride, 
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quantified by HPLC and evaluated according to a standard curve made with known 
amounts of cysteine. 
 
Cytotoxicity assays 
The specific cytotoxic activities of the DARPin-ETA” fusion toxins were assessed by 
measuring cell viability in standard colorimetric XTT assays (XTT = (2,3-bis[2-
methoxy-4-nitro-5-sulfophenyl]-2H-tretrazolium-5-carboxanilide) sodium salt) (Roche, 
Basel, Switzerland). Briefly, EpCAM-positive or negative tumor cells were seeded at 
5000 cells per well in a 96-well plate and incubated overnight at 37°C under standard 
cell culture conditions as described above. The fusion proteins were added to the 
cells at the indicated concentrations to a final volume of 100 µl. After 72 h, 50 µl of 
XTT reagent was added as specified by the manufacturer's protocol and cells were 
further incubated for 2 h. The absorbance at 450 nm was measured with a HTS 7000 
plus microplate reader (Perkin Elmer, Wellesley, USA) and cell viability was 
calculated after subtraction of blanks (wells without cells) as the percentage of living 
cells in treated wells relative to untreated cells (cells without DARPin-ETA” toxin). 
 For competition analysis of specificity, cells were first preincubated for 10 min 
with unconjugated DARPins at the concentrations indicated before Ec4-ETA" was 
added and viability was determined as described above. 
 
Fluorescence labeling of DARPin-ETA" fusion proteins with Cy5.5 
Ec4-ETA" and off7-ETA" were incubated with a 3-fold molar excess of Cy5.5 NHS 
ester (GE Healthcare) pH 7.4 for 1.5 h at room temperature. At this relatively low pH 
the N-terminal amino group is favored over lysine residues at short incubation times 
and modest excess of dye. The samples were passed over a PD-10 column (GE 
Healthcare) to remove unreacted dye and exchange the buffer to 100 mM sodium-
bicarbonate with 20 mM NaCl at pH 8. Monolabeled fusion proteins were separated 
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from unlabeled and multiply labeled proteins by anion exchange chromatography on 
a MonoQ column (GE Healthcare) in 100 mM sodium-bicarbonate and 1 M NaCl at 
pH 8 with isocratic elution. 
 
Animals and tumor xenografts 
For in vivo experiments, 8-10 weeks old female athymic mice (NMRI nu/nu, Harlan 
Laboratories, B.V., The Netherlands or CD1, Charles River, Sulzfeld, Germany) were 
used. Mice were housed and maintained under specific pathogen-free conditions 
according to the guidelines of the veterinary offices of the Kanton Zürich and Bern. 
Tumors were raised by subcutaneous (s.c.) injection into the lateral flank of HT29 or 
SW2 cells (107 cells in 100 µl PBS). 
 
In vivo serum half-life of Ec4-ETA" 
Female nude mice were intravenously injected with a single dose of 30 µg Ec4-ETA" 
in 100 μl of PBS. Blood samples were collected at different time points (3, 5, 10, 20, 
30 and 60 min) from the time of the injection. Serum was harvested from the blood 
samples and the concentration of Ec4-ETA" was determined by ELISA in comparison 
to a standard curve of the corresponding pure immunotoxin.  
 Briefly, microtiter plates were coated with anti-Pseudomonas Exotoxin A 
antibody (Sigma) diluted 1:2000 in PBS overnight at 4°C. Plates were blocked with 
PBS containing 1% BSA (bovine serum albumin) for 2 h at room temperature 
followed by washing four times in PBS containing 0.05% Tween 20. A standard curve 
was made with pure Ec4-ETA" while serum samples were diluted 1:100 and 1:1000 
in PBS. One hundred microliters of standards or samples were applied and incubated 
for 1 hour at room temperature. After washing, anti RGS-His antibody conjugated 
with horseradish peroxidase (Qiagen) diluted 1:2000 was incubated for 1 h at room 
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temperature. After washing, plates were developed using 3,3’-5,5’-
tetramethylbenzidine (TMB) for 15 min and the absorbance was measured at 450 nm  
 
In vivo fluorescence imaging 
Ten days after s.c. tumor cell injection, mice were intravenously (i.v) injected with 30 
μg of Ec4-ETA" or off7-ETA" conjugated with the fluorescent dye Cy5.5 (n=3 for each 
group). In vivo imaging was performed 6, 24, 48, 72, and 96 h after injection. During 
imaging mice were anaesthetized by intraperitoneal (i.p.) injection of body-weight 
adapted doses of 10% ketamine and 2% xylazin. In addition, 48 h after i.v. injection 
one mouse of each group was euthanized and fluorescent images of dissected 
organs were obtained. Images were acquired using the NightOwl II NC100, Type LB 
893, 2006 imaging system (Berthold Technologies, Bad Wildbad, Germany) with an 
exposure time of 60 s. For colocalization of the fluorescent image on the animal 
body, gray scale and pseudocolor images were merged. Quantification of signal 
intensity in all animals was performed with WinLight32 Software. 
 
Anti-tumor activity in vivo 
Mice bearing established HT29 tumors of 50 to 100 mm3 in size were i.v. injected on 
days 1, 3 and 5 with either 30 µg or 20 µg Ec4-ETA" or with 30 µg off7-ETA" in 100 µl 
PBS. Treatment with the lower dose (20 µg) of Ec4-ETA" was repeated again on 
days 9, 13 and 15. Mice bearing established SW2 tumors of 40 to 80 mm3 in size 
were i.v. injected on days 1, 3, 5, 8, 10 and 12 with 20 µg Ec4-ETA" or 20 µg off7-
ETA" in 100 µl PBS. For both tumor models mice treated with PBS at the same time 
points were used as control. 
Animals were monitored for tumor growth by caliper measurement of the shortest 
diameter and the longest perpendicular diameter. Tumor volume was calculated 
according to the formula (short diameter)2 x (long diameter) x 0.4. Mice were 
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euthanized when tumors reached a volume of 1500 mm3 or when tumors showed 
skin ulcerations. 
 
In vivo toxicity determination 
During treatment with the fusion toxins animals were controlled daily for weight loss 
or other signs of toxicity and discomfort (apathy, ungroomed appearance, 
dehydration, etc). Liver toxicity was assessed post mortem by measuring alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) activity in plasma 
samples. Blood samples from 4 mice treated with PBS and 4 mice treated with 30 µg 
Ec4-ETA" three times every second day were collected 24 h after the final injection. 
Upon plasma separation, ALT and AST activities were measured photometrically. 
 
Statistical analysis 
All data represent the mean ± SD. Statistical analyses of in vivo tumor growth were 
performed using the Kruskal-Wallis test. P < 0.05 was considered statistically 
significant. 
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Results 
 
Expression and purification of DARPin-ETA" fusion proteins 
The EpCAM-specific high-affinity DARPin Ec41 and the control DARPins off7 
(29) and E3_5 (30) were fused via a (GSG4)2 linker to a truncated form of 
Pseudomonas exotoxin A (residues Glu252-Pro608, numbering of the mature 
protein), containing a C-terminal KDEL sequence (denoted ETA252-608KDEL or ETA") 
to increase cytotoxicity in mammalian cells (33). For purification and detection, the 
constructs further contained a His6 tag at the C-terminus in front of the KDEL 
sequence and a RGSHis6 tag at the N-terminus. 
 All DARPin-ETA" fusion proteins were expressed in soluble form in E. coli at 
37°C. The protein yield was up to 40 mg/liter of bacterial culture. Purification was 
achieved using immobilized metal ion affinity chromatography (IMAC), which for in 
vivo experiments was followed by extensive Triton X-114 washing, size exclusion 
chromatography and an EndoTrap column to remove endotoxin. The fusion toxins 
showed a band at the predicted molecular weight of around 59 kDa when analyzed 
on SDS-PAGE (Figure 1A), and size exclusion chromatography revealed a mainly 
monomeric fraction (Figure 1B). Figure 1C shows a structural model of Ec4-ETA". 
ETA" contains two disulfide bonds, and although the fusion toxins were expressed in 
the bacterial cytoplasm, and no redox shuffle system was used during purification, 
quantitative disulfide assays (see Materials and Methods) revealed that > 90% of the 
protein had both disulfide bonds formed after purification, most probably by 
spontaneous air oxidation (data not shown). We conclude from these findings that 
DARPins are well suited for the easy and cost-effective production of fusion toxins for 
tumor targeting. 
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EpCAM-binding affinity of Ec4-ETA" 
To investigate whether the fusion to ETA” impaired the binding activity of 
DARPin Ec4 to EpCAM, the association (ka) and dissociation rate constants (kd) of 
both Ec4 and Ec4-ETA” were measured by surface plasmon resonance (SPR) 
(Supplementary Figure 1A and 1B). The measurements revealed that Ec4 and Ec4-
ETA” have comparable rates of association (1.1 × 105 and 6.2 × 104 M-1s-1, 
respectively) and dissociation (1.8 × 10-4 and 1.3 × 10-4 s-1, respectively), resulting in 
similar equilibrium dissociation constants of 1.7 and 2.2 nM. In addition, the 
equilibrium dissociation constant of fluorescently labeled Ec4 to EpCAM-positive 
MCF-7 cells was measured on a flow cytometer, again from the ratio kd/ka. A slightly 
higher KD of 5.8 nM was obtained from association (ka = 5.5 × 104 M-1s-1) and 
dissociation (kd = 3.2 × 10-4 s-1) rate constants (Supplementary Figure 1C and 1D). 
 
Cytotoxicity of Ec4-ETA" against various tumor cell lines in vitro 
The cytotoxic effect of Ec4-ETA” and the control fusion proteins off7-ETA” 
and E3_5-ETA” on various EpCAM-positive tumor cell lines and EpCAM-negative 
control cells was determined in colorimetric XTT cell viability assays upon a 72 h 
incubation. As shown in Fig. 2A, Ec4-ETA” was potently cytotoxic against all EpCAM-
positive cell lines tested, MCF7, SW2, CAL27 and HT29. The IC50 values 
(concentration at which cell viability was reduced by 50%) ranged from less than 
0.005 pM to 0.7 pM. In contrast, the IC50 value on EpCAM-negative RL cells was 
more than 100'000-fold higher (IC50 > 10 nM). Similarly, the unspecific fusion proteins 
off7-ETA" and E3_5-ETA" showed cytotoxic effects only at much higher 
concentrations (IC50 > 1 nM) than the EpCAM-specific ones when tested on EpCAM-
positive HT29 cells (Figure 2B). 
Furthermore, the cytotoxicity of Ec4-ETA" was markedly decreased when 
cells were preincubated with an excess of unfused DARPin Ec4 as competitor 
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(Figure 2C). This decrease was specific for EpCAM blocking, as preincubation with 
the non-specific DARPins off7 and E3_5 did not diminish Ec4-ETA" cytotoxicity. 
Moreover, the use of the unfused DARPins did not affect cell viability (data not 
shown). Taken together, these data show that the cytotoxicity is mediated by 
EpCAM-specific uptake and background cytotoxicity by unspecific uptake of the 
DARPin-ETA" fusion proteins was in general very low. 
 
Tumor localization of Ec4-ETA" 
To demonstrate that Ec4-ETA" efficiently localizes to tumors upon systemic 
administration and that this effect is EpCAM-dependent, in vivo fluorescence imaging 
was performed in athymic mice bearing s.c. HT29 tumor xenografts. Ec4-ETA" and 
off7-ETA" control were N-terminally labeled with the fluorescent dye Cy5.5 (emission 
maximum 680 nm). After the coupling reaction, the labeled proteins were purified by 
anion exchange chromatography to eliminate unlabeled protein, free dye and other 
labeled protein species. Mice were injected i.v. with 30 µg Ec4-ETA"_Cy5.5 or off7-
ETA"_Cy5.5, and images were taken after 6, 24, 48, 72 and 96 h using the 
NightOWL II LB891 imaging system. As shown in Fig. 3A, 6 h after injection both 
fusion proteins localized to the lower abdomen which could be identified as mainly 
kidney and partially liver accumulation. Ec4-ETA" efficiently localized to tumors 24 h 
after injection, and accumulation peaked between 48 h and 72 h before it declined to 
background values after 96 h. In contrast, only very low background fluorescence 
was detectable in the tumors upon injection of the non-targeted fusion protein off7-
ETA".  
Furthermore, we performed ex vivo analysis of biodistribution in isolated 
organs and tumors 48 h after injection of the fluorescent-labeled probe using a fiber 
optic device. As shown in Fig. 3B, similar to whole animal imaging, high fluorescence 
activity in the tumor was detected only in mice injected with Ec4-ETA" but not off7-
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ETA". Probably as a consequence of metabolic degradation, both fusion proteins 
also showed localization in parts of the liver and at low levels in the intestine. These 
signals, however, were covered by overlaying tissue and thus undetectable by in vivo 
imaging.  
 
Serum half-life of Ec4-ETA" in mice 
To determine the serum half life (t ½) of Ec4-ETA", mice were injected with a single 
dose of 30 µg and blood was collected at intervals between 3 and 60 min. The 
concentration of Ec4-ETA" in mouse serum was measured by sandwich ELISA. Each 
data point used to determine half-life represents the average of samples of 2 to 4 
mice.  Data were fit to a single exponential decay function with plateau 
(Supplementary Figure 2) and the serum half-life of Ec4-ETA" was determined as 
11.2 min. 
 
Anti-tumor effect of Ec4-ETA" 
To investigate how the favorable tumor localization of Ec4-ETA" translates 
into therapeutic efficacy, its anti-tumor effect was evaluated in athymic mice bearing 
established s.c. tumor xenografts. As a first tumor model, we used the cell lines 
HT29. In one group, mice received 3 doses of 30 µg Ec4-ETA" (Ec4-ETA" 30/3) on 
days 1, 3 and 5. In a second group, 6 doses of 20 µg Ec4-ETA" (Ec4-ETA" 20/6) 
were administered on days 1, 3, 5, 9, 13 and 15. Control mice received PBS or 3 
doses of 30 µg off7-ETA" (off7-ETA" 30/3) on days 1, 3 and 5. 
As shown in Figure 4A, tumors of control mice treated with PBS grew rapidly 
until the end of the observation period. In contrast, in all mice treated with Ec4-ETA" 
tumor growth was strongly inhibited. Tumors of mice treated with the Ec4-ETA" 30/3 
schedule almost completely disappeared after the last injection, but started to regrow 
when treatment was discontinued. Nonetheless, in this group 2 of 11 mice (18 %) 
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showed complete regression, defined as non-detectable tumor or no tumor regrowth 
for more than 45 d. The anti-tumor effect of the Ec4-ETA" 20/6 schedule was even 
more pronounced, resulting in 2 of 5 mice (40 %) with complete regressions. Lower 
doses of Ec4-ETA" (5 µg) did not result in significant tumor responses (data not 
shown). Treatment with the control fusion protein off7-ETA" 30/3 had no effect on 
tumor growth compared to mice treated with PBS. To better discriminate between the 
response rates in the various groups, Kaplan-Meier curves were plotted with an end 
point defined as a tumor size > 100 mm3. As shown in Figure 4B, all control mice 
treated with PBS or off7-ETA" developed tumors > 100 mm3 already 9 d after the 
start of treatment. At this time point, all mice in the Ec4-ETA"-treated group had 
tumors clearly below this size. On day 31, 18 % of mice treated with Ec4-ETA" 30/3 
and 60 % of mice treated with Ec4-ETA" 20/6 still showed tumors < 100 mm3, 
indicating that treatment with the Ec4-ETA" 20/6 schedule was more effective in 
tumor control than with Ec4-ETA" 30/3. At the end of the experiment (day 31), the 
average size of tumors was significantly reduced from 1005 ± 275 mm3 (PBS group) 
to 188 ± 125 mm3 in the Ec4-ETA" 30/3 treated group (P < 0.05) and to 89 ± 87 mm3 
in the Ec4-ETA" 20/6 treated group (P < 0.05). This reflects a reduction in tumor 
volume of 81 % and 91 %, respectively. The favorable effect of the Ec4-ETA" 20/6 
schedule, which delivered a higher overall dose but without increased toxicity, is also 
reflected by the 40 % complete regressions (see above). The high standard 
deviations observed for Ec4-ETA” are due to the fact that some mice showed 
complete regressions. No difference in tumor size was found in mice treated with 
off7-ETA" 30/3 compared to PBS. 
We confirmed the anti-tumor activity of Ec4-ETA" in a SW2 small cell lung 
carcinoma xenograft model, which shows a slower growth rate and is known to form 
a very solid tumor mass. Mice bearing s.c. SW2 tumors were treated with 6 doses of 
20 µg Ec4-ETA or off7-ETA" on days 1, 3, 5, 8, 10, and 12. As shown in Figure 4C, 
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treatment with Ec4-ETA" decreased the tumor size compared with controls (PBS and 
off7-ETA). On day 31, mice treated with Ec4-ETA" had an average tumor size of 257 
± 114 mm3 whereas mice treated with off7-ETA" and PBS already reached tumor 
sizes of 856 ± 198 mm3 and 776 ± 214 mm3, respectively. There was thus a 
significant reduction in tumor volume of treated compared to PBS control mice (P < 
0.05), although the effect was slightly less pronounced than on faster growing HT29 
tumors. 
 
Toxicity of Ec4-ETA" 
To determine treatment-related unspecific toxicity upon Ec4-ETA" and off7-ETA" 
administration, mice were monitored for weight loss, dehydration and signs of 
distress (apathy, hyperalgesia and ungroomed appearance) throughout the course of 
the study. Representative for all therapy experiments Figure 5 shows for HT29 
tumor-bearing mice that treatments were well-tolerated and after reversible marginal 
weight loss after the third injection of Ec4-ETA” 30/3 no further signs of toxicity were 
observed. Furthermore, to assess liver toxicity as a frequent dose-limiting side effect 
of ETA fusion toxin therapy in patients, blood from 4 PBS-treated mice and 4 mice 
receiving 3 doses of 30 µg Ec4-ETA" was collected and analyzed for activity of the 
liver transaminases aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT). As shown in Table 1, liver toxicity could be excluded for this treatment 
schedule, as there was no significant elevation of ALT and AST activity in the plasma 
of Ec4-ETA"-treated (ALT: 54 ±  22 U/L, and AST: 141 ± 47 U/L ) compared to PBS-
treated mice (ALT: 57 ±  51 U/L, and AST: 99 ± 53 U/L). 
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Discussion 
 
Chemotherapy still has remained the mainstay of cancer therapy. The great 
majority of approved treatments have no inherent specificity for tumor cells but attack 
all dividing cells. More recently many investigations have been carried out to couple a 
toxic principle to a recognition function. Immunotoxins based on Pseudomonas 
aeruginosa exotoxin A (ETA, also termed PE), particularly its truncated variant 
carrying a C-terminal KDEL peptide (ETA"), have been generated against various cell 
surface receptors and extensively tested in preclinical and early clinical studies 
(5,34). Most of them use a single-chain fragment (scFv) or a disulfide-stabilized dsFv 
fragment of antibodies as targeting moiety. We previously also reported on the potent 
anti-tumor effect of an EpCAM-specific scFv-ETA" immunotoxin (11), which is 
currently under phase II clinical investigation (9). 
Commonly used antibody Fv-based formats, however, are difficult to produce 
in high amounts when compared to other proteins and are often aggregation-prone 
(24,26,35). ScFv and dsFv fragments used for tumor-targeted fusion proteins must 
either be expressed in the periplasm or refolded after expression in inclusion bodies. 
Here, we investigated another class of highly advanced binding molecules, Designed 
Ankyrin Repeat Proteins (DARPins), for targeted delivery of ETA" to tumor cells in 
vitro and in vivo. DARPins can be selected for high affinity, which is a major 
requirement for efficient tumor targeting (36), their inherent robustness allows easy 
conjugation with various types of effector molecules, and pharmacology and tumor 
targeting properties can be easily modulated, e.g. by site-specific PEGylation. 
Therefore, we are not limited to the simple fusions described here, as the molecules 
are robust enough to allow efficient production of more complicated constructs. As 
shown recently, the possibility to produce DARPins in functional form in multi-gram 
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amounts by fermentation of E. coli and their easy purification can significantly reduce 
the time from preclinical development to clinical investigation2  
We are expressing the DARPin-ETA" fusions in the cytoplasm of E. coli and 
find that these fusion proteins are produced in soluble form. Even though the ETA 
part contains two disulfide bonds, which appear to be beneficial in the internalization 
process (37), we find in the purified protein that they have been formed almost 
quantitatively, possibly by air oxidation. Thus, we can use the convenient production 
of DARPins in the E. coli cytoplasm also with the DARPin-ETA" fusion proteins. 
A major challenge for the application of immunotoxins is the choice of targets 
which provide sufficient tumor specificity and, at the same time, promote intracellular 
delivery of the payload. Several targets have been explored which serve this 
purpose, e.g. EGFR, LewisY, and various hematopoietic markers (2). Most tumor-
targeting with fusion toxins has been studied in hematopoietic malignancies, but even 
there, only one (denileukin diftitox, Ontak®), a fusion of IL-2 with diphtheria toxin, 
finally received FDA approval (38).  
EpCAM is overexpressed in many solid tumors and on the basolateral cell 
surfaces of some normal epithelia (15,18) where it is, however, poorly accessible to 
circulating anti-EpCAM antibodies (17). Since it also occurs on normal hepatic stem 
cells and hepatoblasts, EpCAM-targeted immunotherapy may in principle impair liver 
regeneration. However, liver toxicity has never been reported in clinical trials with 
anti-EpCAM antibodies, probably because the regenerative capacity of the adult liver 
is sufficiently maintained by mitotic division of mature hepatocytes (39). In contrast, 
the inherent liver toxicity of ETA is based on inflammatory responses caused by liver 
macrophages, independent on specific hepatocyte targeting (40).  
                                                 
2 http://clinicaltrials.gov/ct2/show/NCT01042678, 
http://clinicaltrials.gov/ct2/show/NCT01086761. 
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Recently, EpCAM was also identified as a marker of cancer-initiating cells in 
colon (21), breast (22), pancreatic (23) and hepatocellular carcinomas (24). Since 
cancer stem cells respond poorly to standard therapy and thus are largely 
responsible for treatment failure, their elimination must be a prime objective for all 
kinds of innovative cancer therapy. Thus, from a therapeutic point of view, EpCAM is 
particularly interesting as a docking site for targeting ligands delivering external 
effector molecules. In fact, EpCAM efficiently mediates internalization of bound 
ligands by receptor-mediated endocytosis and thus perfectly matches the need of 
anti-cancer agents acting on intracellular targets, such as protein toxins, 
chemotherapeutic agents, and antisense compounds (11-13).  
Recently, we have described for the first time the production and biochemical 
characterization of EpCAM-specific DARPins, and a first generation binder was used 
to successfully deliver therapeutic siRNA into tumor cells in the form of mono- and 
multivalent binders fused to highly charged protamine (14). Subsequent affinity 
maturation efforts then resulted in DARPin Ec4, which displayed affinity to EpCAM in 
the nanomolar range and excellent biophysical properties1. 
We measured efficient tumor localization of Ec4-ETA", but not of the control 
fusion off7-ETA", by in vivo fluorescence imaging upon systemic administration in a 
HT29 colon carcinoma xenograft model. These data showed that localization in the 
tumor was specific and dependent on EpCAM binding with peak tumor accumulation 
48-72 h after injection.  
Fluorescent imaging records the distribution of molecules at any particular 
time point, while the previously used residualizing label 99mTc(CO)3 (36) gives an 
integral localization since the begin of injection, since any label will accumulate at the 
site of cellular internalization. This probably accounts for the difference in kidney 
accumulation, which is seen to decay rapidly when measured by fluorescent imaging 
but not by 99mTc(CO)3 radioactivity. While immunotoxins (scFv fragments or DARPins 
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fused to a protein toxin such as ETA) would be expected to not fall in an ideal MW 
range for maximum accumulation (36), we see very encouraging enrichments and 
therapeutic effects already with the constructs described here, and there may be 
even better effects with different molecular formats. 
In the present study, Ec4 was fused with ETA" to assess for the first time the 
potential of a rationally engineered DARPin for tumor targeting and therapy. The 
fusion protein could indeed be well produced in soluble form in E. coli at about 80-
fold higher yield from shake flasks than our previously described scFv-ETA" fusion 
toxin (4D5MOCB-ETA) (11), could be easily purified and was stable and resistant to 
aggregation. This will facilitate subsequent scaling up of the production process 
required for clinical trials.  
We found that the high-affinity binding of Ec4 to intact cells was fully 
preserved upon fusion with ETA" and that Ec4-ETA" showed extremely high and 
specific in vitro cytotoxicity against EpCAM-positive tumor cells of various histotypes 
with IC50 values of 0.005 pM. This is remarkably low compared to other immunotoxins 
(41-43) and likely mirrors its high stability, affinity and efficient internalization by 
receptor-mediated endocytosis. These data, combined with efficient tumor targeting, 
indeed translated into potent anti-tumor effects at well-tolerated doses with some 
mice showing complete regression of their tumors. The higher overall dose 
administered as 6 x 20 μg could prove more effective then the lower dose schedule 
(3 x 30 μg). Probably due to the short half-life of the DARPin-ETA" fusion toxin in the 
circulation which may limit tumor accumulation but also toxicity to normal tissues, the 
dose required to achieve tumor responses was higher than for a previously described 
scFv-ETA" immunotoxin (11). The repeatable response measured after repeated 
injections further suggests that tumors retained a stable EpCAM expression profile 
and that antigen loss did not occur during treatment.  
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A phase II study with this previously reported EpCAM-specific immunotoxin  
(11) consisting of ETA" fused to a scFv antibody is ongoing and will be completed 
soon (9). Based on the findings of the present study, it is tempting to speculate that 
DARPins like Ec4 can replace the antibody fragment as cell binding ligands also in 
forthcoming generations of tumor-targeted fusion toxins as well as other drug delivery 
systems. 
In summary, we describe for the first time the generation and preclinical 
evaluation of an EpCAM-specific fusion toxin consisting of a high-affinity DARPin 
(Ec4) and ETA" as a catalytic biotoxin. We provide evidence for its potent activity 
against various tumor cell types in vitro, and its favorable tumor localization and anti-
tumor activity in vivo. The advantages of DARPins enabling high yield expression, 
resistance against aggregation, and stability also in the form of fusion toxins in 
conjunction with a tumor-associated target like EpCAM, opens new avenues for the 
generation of rationally designed protein therapeutics with outstanding efficacy. 
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Figure Legends  
 
Figure 1. Biochemical characterization of the DARPin-ETA” fusion toxins. A For 
SDS-PAGE analysis, fractions were loaded onto a 10% polyacrylamide gel and 
proteins were detected by staining with Coomassie brilliant blue: lane M: molecular 
weight marker (kDa), lane 1: uninduced bacterial cell lysate, lane 2: cell lysate 4 h 
after induction, lane 3: purified Ec4-ETA”, lane 4: purified off7-ETA”, and lane 5: 
purified E3_5-ETA”. B Size exclusion chromatography of DARPin-ETA” fusion toxins 
analyzed on a Superdex 200 10/300 GL column. C Model of the DARPin-toxin 
construct was built based on the X-ray structures of a consensus DARPin (PDB entry 
2QYJ) and Pseudomonas aeruginosa exotoxin A (ETA) (1IKQ) using InsightII 
(Accelrys) and the ROSETTA suite programs. The DARPin targeting moiety is shown 
in cyan, ETA domain Ib in purple, domain II in orange and domain III in red. The 
flexible N-terminal RGS-His6-tag, the C-terminal His6 tag and KDEL ER-retention 
signal (blue) as well as the linker connecting the DARPin to the toxin (green) were 
modeled in to visualize their sizes relative to those of the protein domains. The figure 
was generated using the program PyMol (DeLano Scientific LLC, Palo Alto, CA, 
USA). 
 
Figure 2. In vitro cytotoxicity of Ec4-ETA” and the control fusion toxins off7-ETA” and 
E3_5-ETA” tested on various tumor cell lines. A The EpCAM-positive cell lines 
MCF7, SW2, CAL27, HT29, and the EpCAM-negative cell line RL were incubated for 
72 h with different concentrations of Ec4-ETA” before cell viability was determined in 
colorimetric XTT assays. B. HT29 cells were incubated with the unspecific fusion 
proteins E3_5-ETA” or off7-ETA” for 72 h in XTT assays, and viability was compared 
to cells treated with Ec4-ETA”. C In competition assays, EpCAM-positive HT29 cells 
were incubated with DARPin Ec4, E3_5 and off7 (500 nM) 10 min before Ec4-ETA” 
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was added and cell viability determined as described above. All determinations were 
done in triplicates, data represent the mean ± SD 
 
Figure 3. Tumor localization and organ distribution of Cy5.5-labeled Ec4-ETA" and 
the off7-ETA" control fusion toxin detected by in vivo fluorescence imaging. Mice 
bearing s.c. HT29 tumor xenografts were intravenously (i.v) injected with 30 μg of 
Ec4-ETA” or off7-ETA" conjugated with the fluorescent dye Cy5 (n=3 for each group). 
A In vivo images were acquired 6, 24, 48, 72, and 96 h after injection using the 
NightOWL II LB891 imaging system with an exposure time of 60 s. For colocalization 
of the fluorescent image on the animal body, gray scale and pseudocolor images 
were merged. ND: not determined. B Ex vivo analysis of fluorescence intensities 
from isolated tumors and organs 48 h after injection of Cy5.5-labeled Ec4-ETA" or 
off7-ETA" using a fiber optic device. Organs of one representative mouse of each 
group is shown. Data are plotted as the average of two mice; bars, SD 
 
 
Figure 4. Anti-tumor effect of Ec4-ETA” in athymic mice. A. Mice bearing s.c. 
growing HT29 tumor xenografts of 50 to 100 mm3 in size received tail-vein injections 
of either 3 x 30 µg Ec4-ETA”, 3 x 30 µg off7-ETA” control, 6 x 20 µg Ec4-ETA” or 
PBS as vehicle control. Tumor growth was monitored by caliper measurement during 
the course of 31 days. Data represent the mean tumor volume ± SD of 5 to 11 mice 
per group. B Kaplan-Meier survival curves with an endpoint defined as tumor volume 
of 100 mm3. The curves show the percentage of treated mice in each group in which 
tumors did not exceeded 100 mm3 in size at the various time points after the start of 
treatment. C Mice bearing s.c. growing SW2 tumor xenografts of 40 to 80 mm3 in size 
received tail-vein injections of either 6 x 20 µg Ec4-ETA”, 6 x 20 µg off7-ETA” control, 
or PBS as vehicle control. Tumor growth was monitored by caliper measurement 
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during the course of 31 days. Data represent the mean tumor volume ± SD of 5 to 6 
mice per group. D Pictures of representative tumors isolated from mice of the 
different treatment groups. 
 
Figure 5. Average weight of mice upon treatment with different dose schedules of 
Ec4-ETA", or off-7-ETA" or with PBS control. Animals were weighed three times per 
week during the whole experiment to monitor treatment-related toxicity.  
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Table 1. Liver transaminase activity in the plasma from mice treated with Ec4-ETA”
Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 1 Mouse 2 Mouse 3 Mouse 4
ALT U/L 34 84 57 41 134 40 26 29
AST U/L 141 200 138 85 177 62 86 70
*Mice received 3 x 30 g of Ec4-ETA” or PBS i.v. Activity of the transaminases was measured 24 h after the final injection.
 ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Treatment *
Ec4-ETA" PBS
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